JOURNEY MEDICAL CORP (DERM)

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults;...

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T....

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral...

SWK Holdings Provides Portfolio Update

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...

Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference

SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...

Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...

DERM Stock Earnings: Journey Medical Misses EPS, Beats Revenue for Q2 2024

DERM stock results show that Journey Medical missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

DERM Stock Earnings: Journey Medical Misses EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Journey Medical (NASDAQ:DERM) just reported results for the second quarter of 2...

Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June...

Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

Company to host conference call to discuss financial results and provide a corporate update on August 12, 2024 at 4:30 p.m. ET...

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical...

Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...

DERM Stock Earnings: Journey Medical Beats EPS, Misses Revenue for Q1 2024

DERM stock results show that Journey Medical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

DERM Stock Earnings: Journey Medical Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Journey Medical (NASDAQ:DERM) just reported results for the first quarter of 20...

Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter...

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET...

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...

Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024

SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage...

3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024

Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.

DERM Stock Earnings: Journey Medical Beats EPS, Beats Revenue for Q4 2023

DERM stock results show that Journey Medical beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

DERM Stock Earnings: Journey Medical Beats EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Journey Medical (NASDAQ:DERM) just reported results for the fourth quarter of 2...

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 ...

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024...

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET...

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical...

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that...

Journey Medical submits NDA for DFD-29 for rosacea (NASDAQ:DERM)

Journey Medical (FBIO) said it has submitted a New Drug Application for its rosacea treatment DFD-29. The product is being developed with Dr. Reddy's (RDY). Read more here.